A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the north central cancer treatment group
- 1 May 1993
- Vol. 71 (9), 2723-2726
- https://doi.org/10.1002/1097-0142(19930501)71:9<2723::aid-cncr2820710906>3.0.co;2-2
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Phase II Trial of Amonafide in Patients with Stage III and IV Non-Small-Cell Lung CancerAmerican Journal of Clinical Oncology, 1991
- Phase II Trial of Trimetrexate in Patients with Stage III and IV Non-Small-Cell Lung CancerAmerican Journal of Clinical Oncology, 1989
- Phase I Trial of Trimetrexate Glucuronate on a Five-Day Bolus Schedule: Clinical Pharmacology and PharmacodynamicsJNCI Journal of the National Cancer Institute, 1989
- Trimetrexate: Predictors of Severe or Life-Threatening Toxic EffectsJNCI Journal of the National Cancer Institute, 1988
- Correlates of Severe or Life-Threatening Toxic Effects From TrimetrexateJNCI Journal of the National Cancer Institute, 1988
- Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.Journal of Clinical Oncology, 1988
- Confidence Intervals for a Binomial Parameter Based on Multistage TestsBiometrics, 1987
- Evaluation of response criteria in advanced lung cancerCancer, 1979
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958